电子健康记录中被动选择与主动选择干预对心内科医生他汀处方的影响:一项集群随机临床试验
6个月干预后,两种干预均未显著改变最佳剂量他汀处方率,但在临床ASCVD亚组中主动选择干预使最佳剂量他汀处方率小幅显著增加。
要点
- 被动选择与主动选择EHR干预均未显著改变整体最佳剂量他汀处方率。
- 在临床ASCVD患者亚组中,主动选择干预使最佳剂量他汀处方率显著增加3.8个百分点。
- 两种干预对任何剂量他汀处方率均无显著影响。
核心结论
- 被动选择和主动选择EHR干预未改变整体他汀处方率。
- 在临床ASCVD亚组中,主动选择干预使最佳剂量他汀处方率小幅显著增加,可指导未来干预设计或靶向。
主要发现
- 最佳剂量他汀处方率基线:对照组40.3%,被动选择组39.1%,主动选择组41.2%。
- 两种干预对任何剂量他汀处方率均无显著变化。
临床怎么用
- 主动选择EHR干预可能对临床ASCVD患者的最佳剂量他汀处方有小幅提升作用,可考虑用于该亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Statin therapy is underused for many patients who could benefit. OBJECTIVE: To evaluate the effect of passive choice and active choice interventions in the electronic health record (EHR) to promote guideline-directed statin therapy. DESIGN, SETTING, AND PARTICIPANTS: Three-arm randomized clinical trial with a 6-month preintervention period and 6-month intervention. Randomization conducted at the cardiologist level at 16 cardiology practices in Pennsylvania and New Jersey. The study included 82 cardiologists and 11 693 patients. Data were analyzed between May 8, 2019, and January 9, 2020. INTERVENTIONS: In passive choice, cardiologists had to manually access an alert embedded in the EHR to select options to initiate or increase statin therapy. In active choice, an interruptive EHR alert prompted the cardiologist to accept or decline guideline-directed statin therapy. Cardiologists in the control group were informed of the trial but received no other interventions. MAIN OUTCOMES AND MEASURES: Primary outcome was statin therapy at optimal dose based on clinical guidelines. Secondary outcome was statin therapy at any dose. RESULTS: The sample comprised 11 693 patients with a mean (SD) age of 63.8 (9.1) years; 58% were male (n = 6749 of 11 693), 66% were White (n = 7683 of 11 693), and 24% were Black (n = 2824 of 11 693). The mean (SD) 10-year atherosclerotic cardiovascular disease (ASCVD) risk score was 15.4 (10.0); 68% had an ASVCD clinical diagnosis. Baseline statin prescribing rates at the optimal dose were 40.3% in the control arm, 39.1% in the passive choice arm, and 41.2% in the active choice arm. In adjusted analyses, the change in statin prescribing rates at optimal dose over time was not significantly different from control for passive choice (adjusted difference in percentage points, 0.2; 95% CI, -2.9 to 2.8; P = .86) or active choice (adjusted difference in percentage points, 2.4; 95% CI, -0.6 to 5.0; P = .08). In adjusted analyses of the subset of patients with clinical ASCVD, the active choice intervention resulted in a significant increase in statin prescribing at optimal dose relative to control (adjusted difference in percentage points, 3.8; 95% CI, 1.0-6.4; P = .008). No other subset analyses were significant. There were no significant changes in statin prescribing at any dose for either intervention. CONCLUSIONS AND RELEVANCE: The passive choice and active choice interventions did not change statin prescribing. In the subgroup of patients with clinical ASCVD, the active choice intervention led to a small increase in statin prescribing at the optimal dose, which could inform the design or targeting of future interventions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03271931.
引用
- Adusumalli S, Westover JE, Jacoby DS, et al. Effect of Passive Choice and Active Choice Interventions in the Electronic Health Record to Cardiologists on Statin Prescribing: A Cluster Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 33031534. doi:10.1001/jamacardio.2020.4730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。